
Opinion|Videos|July 26, 2024
Cyclosporine Ophthalmic Solution for Inflammatory Dry Eye
Author(s)Alice Epitropoulos, MD, Laura M. Periman, MD
Dry eye experts discuss Cyclosporine ophthalmic solution.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
1. Cyclosporine ophthalmic solution, 0.1% (VEVYE)
Advertisement
Related to this article

In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.

Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.

Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5



